Crispr Therapeutics shares tumble after significant earnings miss
Miles Patrick, the CEO of Alphatec Holdings , Inc. (NASDAQ:ATEC), recently sold 32,393 shares of the company’s common stock. The transactions, which took place on February 26, 2025, were executed at a weighted average price of $10.89 per share, resulting in a total sale value of approximately $352,759. According to InvestingPro data, ATEC’s stock has surged 75% over the past six months, with analysts setting price targets ranging from $10 to $22.50. These sales were carried out under a pre-established Rule 10b5-1 trading plan, which was adopted in June 2024 to address tax obligations related to the vesting of restricted stock units.
Following the transaction, Patrick retains direct ownership of 5,940,391 shares of Alphatec Holdings. Additionally, he holds 10,900 shares indirectly through an IRA and another 250,000 shares via MOM, LLC. The CEO’s actions are closely monitored by investors as they provide insights into management’s perspective on the company’s future.
In other recent news, Alphatec Holdings Inc. announced its Q4 2024 financial results, showing a revenue of $177 million, which exceeded analyst expectations of $170.35 million. This represents a 28% year-over-year increase. However, the company’s earnings per share (EPS) fell short of forecasts, reporting -$0.23 against an expected -$0.05. Despite the revenue beat, the EPS miss was notable. In terms of future guidance, Alphatec projects its 2025 revenue to reach $732 million, indicating a 20% growth from 2024. The company also anticipates positive cash flow and an adjusted EBITDA of $75 million in 2025. Additionally, Alphatec highlighted its strategic focus on product launches, including navigation robotics expected later in 2025. These developments come as the company continues to expand its market presence and operational efficiency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.